Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 10/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614474 | 1.00 | PDE2A (0.44) | PDE2APTGER4PTGER2TRPV1PTGDR | |
| SCHEMBL22776910 | 1.00 | PDE2A (0.44) | PDE2APTGER4PTGER2TRPV1PTGDR | |
| SCHEMBL22776614 | 0.91 | PTGER4 (0.53) | PDE2APTGER4PTGER2PTGDR | |
| SCHEMBL22776466 | 0.91 | PTGER4 (0.53) | PDE2APTGER4PTGER2PTGDR | |
| SCHEMBL29527734 | 0.91 | PTGER4 (0.53) | PDE2APTGER4PTGER2PTGDR | |
| SCHEMBL22791345 | 0.83 | PTGER4 (0.57) | PTGER4PTGER2PTGDR | |
| SCHEMBL22776437 | 0.82 | PTGER4 (0.44) | PDE2APTGER4PTGER2PTGDRGPR139 | |
| SCHEMBL22776436 | 0.82 | PTGER4 (0.44) | PDE2APTGER4PTGER2PTGDRGPR139 | |
| SCHEMBL22776632 | 0.81 | PTGER4 (0.45) | PDE2APTGER4PTGER2PTGDRGPR139 | |
| SCHEMBL22776633 | 0.81 | PTGER4 (0.45) | PDE2APTGER4PTGER2PTGDRGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | PTGER4, PTGER1, PTGER2 | PDE2A 424/4885PTGER4 1/4885PTGER2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.